Abhimanyu Verma has sold SOPH and made no open-market buys since Jun 2026

Abhimanyu (Abhi) Verma is a healthcare technology leader and Executive Vice President, Chief Technology Officer at SOPHiA GENETICS SA, where he has served since February 2022.( Based in Switzerland, he oversees technology and information strategy, operating models, product development, and operational platforms that support the SOPHiA DDM™ data-driven medicine platform and the company’s broader mission in precision health.( He recently reported selling 6,944 ordinary shares of SOPHiA GENETICS in an open-market transaction to cover tax withholding obligations related to restricted stock unit vesting, under a pre-established Rule 10b5-1(c) trading plan, and continues to hold a substantial equity stake in the company.(

Verma brings more than 17 years of life sciences industry experience focused on the intersection of people, science, technology, data, and AI across multiple therapeutic areas and functions in the pharma value chain.( Before joining SOPHiA GENETICS, he served as VP and Head of Data Science and AI Enablement at Novartis, where he helped innovate and scale data science and technology products and methodologies.( He is also co‑founder and board member of the nonprofit Health Hacking Lab, reflecting his interest in patient‑centric health innovation.( Verma holds an M.B.A. from the Indian School of Business, a Master of Science in pharmaceutical medicine, and an engineering degree, and he is recognized for leading multifunctional organizations, building high‑performing teams, and driving organizational and cultural transformation with a strong focus on execution and measurable outcomes.(

Written by Perplexity from public sources.